Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy.
Gross S, Ihlow J, Busack L, Adamiak K, Schrezenmeier J, Jesse J, Schwarz M, Flörcken A, Vuong LG, Rieger K, Krönke J, le Coutre P, Boldt V, von Brünneck AC, Horst D, Burmeister T, Blau IW, Keller U, Bullinger L, Westermann J. Gross S, et al. Among authors: rieger k. Blood Cancer J. 2024 Sep 16;14(1):160. doi: 10.1038/s41408-024-01140-5. Blood Cancer J. 2024. PMID: 39284846 Free PMC article.
The PROPr can be measured using different PROMIS domain item sets.
Klapproth CP, Fischer F, Doehmen A, Kock M, Rohde J, Rieger K, Keilholz U, Rose M, Obbarius A. Klapproth CP, et al. Among authors: rieger k. Cancer Epidemiol. 2024 Dec;93:102658. doi: 10.1016/j.canep.2024.102658. Epub 2024 Sep 10. Cancer Epidemiol. 2024. PMID: 39260316 Free article.
The EORTC QLU-C10D distinguished better between cancer patients and the general population than PROPr and EQ-5D-5L in a cross-sectional study.
Döhmen A, Obbarius A, Kock M, Nolte S, Sidey-Gibbons CJ, Valderas JM, Rohde J, Rieger K, Fischer F, Keilholz U, Rose M, Klapproth CP. Döhmen A, et al. Among authors: rieger k. J Clin Epidemiol. 2024 Nov 7;177:111592. doi: 10.1016/j.jclinepi.2024.111592. Online ahead of print. J Clin Epidemiol. 2024. PMID: 39515489 Free article.
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, Femia A, Chu M, Musiek ACM, Sluzevich JC, Graham LV, Fernandez AP, Aggarwal R, Rieger K, Page KM, Li X, Hyde C, Rath N, Sloan A, Oemar B, Banerjee A, Salganik M, Banfield C, Neelakantan S, Beebe JS, Vincent MS, Peeva E, Vleugels RA. Fiorentino D, et al. Among authors: rieger k. Lancet. 2025 Jan 11;405(10473):137-146. doi: 10.1016/S0140-6736(24)02071-3. Lancet. 2025. PMID: 39798982 Clinical Trial.
294 results